Literature DB >> 27709447

Current views on HIV-1 latency, persistence, and cure.

Zora Melkova1,2, Prakash Shankaran3, Michaela Madlenakova3,4, Josef Bodor4.   

Abstract

HIV-1 infection cannot be cured as it persists in latently infected cells that are targeted neither by the immune system nor by available therapeutic approaches. Consequently, a lifelong therapy suppressing only the actively replicating virus is necessary. The latent reservoir has been defined and characterized in various experimental models and in human patients, allowing research and development of approaches targeting individual steps critical for HIV-1 latency establishment, maintenance, and reactivation. However, additional mechanisms and processes driving the remaining low-level HIV-1 replication in the presence of the suppressive therapy still remain to be identified and targeted. Current approaches toward HIV-1 cure involve namely attempts to reactivate and purge HIV latently infected cells (so-called "shock and kill" strategy), as well as approaches involving gene therapy and/or gene editing and stem cell transplantation aiming at generation of cells resistant to HIV-1. This review summarizes current views and concepts underlying different approaches aiming at functional or sterilizing cure of HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27709447     DOI: 10.1007/s12223-016-0474-7

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.099


  187 in total

1.  Development of a human adaptive immune system in cord blood cell-transplanted mice.

Authors:  Elisabetta Traggiai; Laurie Chicha; Luca Mazzucchelli; Lucio Bronz; Jean-Claude Piffaretti; Antonio Lanzavecchia; Markus G Manz
Journal:  Science       Date:  2004-04-02       Impact factor: 47.728

2.  R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors.

Authors:  Françoise Gondois-Rey; Angelique Biancotto; Marcelo Antonio Fernandez; Lise Bettendroffer; Jana Blazkova; Katerina Trejbalova; Marjorie Pion; Ivan Hirsch
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

3.  A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy.

Authors:  Adam M Spivak; Adriana Andrade; Evelyn Eisele; Rebecca Hoh; Peter Bacchetti; Namandjé N Bumpus; Fatemeh Emad; Robert Buckheit; Elinore F McCance-Katz; Jun Lai; Margene Kennedy; Geetanjali Chander; Robert F Siliciano; Janet D Siliciano; Steven G Deeks
Journal:  Clin Infect Dis       Date:  2013-12-12       Impact factor: 9.079

4.  Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.

Authors:  Sifei Xing; Cynthia K Bullen; Neeta S Shroff; Liang Shan; Hung-Chih Yang; Jordyn L Manucci; Shridhar Bhat; Hao Zhang; Joseph B Margolick; Thomas C Quinn; David M Margolis; Janet D Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

5.  Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough.

Authors:  Yefei Han; Yijie B Lin; Wenfeng An; Jie Xu; Hung-Chih Yang; Karen O'Connell; Dominic Dordai; Jef D Boeke; Janet D Siliciano; Robert F Siliciano
Journal:  Cell Host Microbe       Date:  2008-08-14       Impact factor: 21.023

6.  PSF acts through the human immunodeficiency virus type 1 mRNA instability elements to regulate virus expression.

Authors:  Andrei S Zolotukhin; Daniel Michalowski; Jenifer Bear; Sergey V Smulevitch; Abdulmaged M Traish; Rui Peng; James Patton; Ivan N Shatsky; Barbara K Felber
Journal:  Mol Cell Biol       Date:  2003-09       Impact factor: 4.272

7.  Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.

Authors:  Hung-Chih Yang; Sifei Xing; Liang Shan; Karen O'Connell; Jason Dinoso; Anding Shen; Yan Zhou; Cynthia K Shrum; Yefei Han; Jun O Liu; Hao Zhang; Joseph B Margolick; Robert F Siliciano
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

8.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

9.  Generation of HIV latency in humanized BLT mice.

Authors:  Paul W Denton; Rikke Olesen; Shailesh K Choudhary; Nancy M Archin; Angela Wahl; Michael D Swanson; Morgan Chateau; Tomonori Nochi; John F Krisko; Rae Ann Spagnuolo; David M Margolis; J Victor Garcia
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

10.  A candidate anti-HIV reservoir compound, auranofin, exerts a selective 'anti-memory' effect by exploiting the baseline oxidative status of lymphocytes.

Authors:  B Chirullo; R Sgarbanti; D Limongi; I L Shytaj; D Alvarez; B Das; A Boe; S DaFonseca; N Chomont; L Liotta; E Iii Petricoin; S Norelli; E Pelosi; E Garaci; A Savarino; A T Palamara
Journal:  Cell Death Dis       Date:  2013-12-05       Impact factor: 8.469

View more
  5 in total

1.  HIV-1 latent reservoir: size matters.

Authors:  Flavia Hodel; Marion Patxot; Tiia Snäkä; Angela Ciuffi
Journal:  Future Virol       Date:  2016-11-28       Impact factor: 1.831

2.  SUN2 Modulates HIV-1 Infection and Latency through Association with Lamin A/C To Maintain the Repressive Chromatin.

Authors:  Wei-Wei Sun; Shi Jiao; Li Sun; Zhaocai Zhou; Xia Jin; Jian-Hua Wang
Journal:  MBio       Date:  2018-05-01       Impact factor: 7.867

3.  Clinical Course of Opportunistic Infections-Toxoplasmosis and Cytomegalovirus Infection in HIV-Infected Patients in Slovakia.

Authors:  Katarína Šimeková; Elena Nováková; Róbert Rosoľanka; Jana Masná; Daniela Antolová
Journal:  Pathogens       Date:  2019-11-04

4.  CD4+CD38+ central memory T cells contribute to HIV persistence in HIV-infected individuals on long-term ART.

Authors:  Cheng-Bo Song; Le-Le Zhang; Xian Wu; Ya-Jing Fu; Yong-Jun Jiang; Hong Shang; Zi-Ning Zhang
Journal:  J Transl Med       Date:  2020-02-24       Impact factor: 5.531

5.  Parasitic and Vector-Borne Infections in HIV-Positive Patients in Slovakia-Evidence of an Unexpectedly High Occurrence of Anaplasma phagocytophilum.

Authors:  Katarína Šimeková; Ľubomír Soják; Bronislava Víchová; Lenka Balogová; Júlia Jarošová; Daniela Antolová
Journal:  Pathogens       Date:  2021-11-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.